SensNews Nov 2017

17 Sensor100 November 2017 Healthcare Hikma invests in diabetes biosensor start-up Hikma Pharmaceuticals, Jordan’s largest drug-maker, is investing in US-based bio- sensor technology firm Biolinq, as the firm looks to lessen its dependence on its generics business line. Biolinq manufactures wirelessly-enabled biosensor patches that can continuously monitor multiple biomarkers.The company’s first commercial product allow pa- tients with diabetes to monitor their blood glucose levels in a minimally-invasive way. Reported by: The National 2 9 November Editorial: Paper-based assays as useful tools for clinical bioanalysis In this timely review, Dr. Marzo discusses paper based sensors based on dipsticks, lateral flow and microfluidics. Reported by: Bioanalysis Zone November FDA approves pill with digital tracking device you swallow A psychiatric medication system in the form of a pill with a built-in digital tracking device gained approval from the US Food and Drug Administration. Abilify MyCite, a form of aripiprazole and a first-of-its-kind product, has an embedded ingestible sensor that records when the medication is taken. Made by Japan-based Otsuka Pharmaceutical Co., the medication system is intended to treat schizophrenia, bi- polar I disorder and depression in adults. The sensor sends signal to a wrist patch, developed by Proteus Digital Health. Reprted by: CNN November 15 By: Dr.Adaris M. López Marzo Vall d’Hebron Hospital Research Institute; Barcelona, Spain